Skip to content
TrialMatch
Sign up
Recruiting Phase 2

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

Create a profile to match View the full record on ClinicalTrials.gov

About this study

To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).

Condition
AMCI - Amnestic Mild Cognitive Impairment, Sleep Disturbance
Tested
Trazodone, Placebo
Sponsor
Johns Hopkins University

Who can join

Age
55 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 11

  • Minimum age: 55 years
  • Study condition: AMCI - Amnestic Mild Cognitive Impairment, Sleep Disturbance
  • Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjective memory complaint and/or objective evidence of memory problems;
  • Clinical Dementia Rating (CDR) of 0.5 with a Memory Box score of \>=0.5;
  • Evidence of sleep complaints with Pittsburgh Sleep Quality Index score of \>5 (a well-validated cutoff observed in \>40% of older persons);
  • Memory performance \> 1.5 Standard Deviation (SD) below age-and education-matched control subjects on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) List Recall;
  • Visual and auditory acuity adequate for neuropsychological testing;
  • Good general health with no disease expected to interfere with the study;
  • Able to have Magnetic Resonance Imaging (MRI) scan;
  • Availability of knowledgeable informant (KI)
  • Buschke Selective Reminding Test or more standard deviations below age-education norms

Exclusion 14

  • Less than 55 years of age to reduce likelihood of including individuals with frontotemporal dementia or non-dementia MCI;
  • Too frail or medically unstable to undergo study procedures;
  • Prior diagnosis of Obstructive Sleep Apnea (OSA) or evidence of moderate-to-severe OSA on baseline Home Sleep Test (HST) as evidenced by an apnea/hypopnea index of \>15;
  • Dementia;
  • Cognitive complaints and deficits better explained by other medical/neurologic conditions;
  • Delirium;
  • Allergic to trazodone;
  • Taking sleep medications including trazodone;
  • Current substance abuse;
  • Current major depressive, manic, or acute psychotic episode;
  • Prior diagnosis of significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol or represent alternate primary cause of memory problems beyond Alzheimer's Disease (AD) pathology:
  • Lack of available KI;
  • Prior diagnosis of Q wave T wave Corrected for heart rate (QTc) \> 470 msec (females) or \> 450 msec (males);
  • Inability to provide informed consent

Where

1 site, 1 recruiting

Johns Hopkins Hospital

Baltimore, Maryland, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.